Neuren Pharmaceuticals EU Approval|36% Surge Masks Reimbursement Risk

Chapter 1: The Reversal Nobody Expected

Neuren Pharmaceuticals surged 36.1 per cent to $16.60 on 30 June after the European Medicines Agency reversed its own earlier rejection of Daybu, the company's Rett syndrome drug.

The reversal is the unusual part. In February 2026, the EMA's Committee for Medicinal Products for Human Use refused to recommend Daybu, citing perceived deficits in the pivotal Lavender trial data.

Neuren's own CEO, Jon Pilcher, said at the time that only 20 to 30 per cent of CHMP decisions were overturned on appeal.

Daybu was one of those rare exceptions. The CHMP adopted a positive opinion, and the decision now moves to the European Commission for a final ruling expected within months.

The stock was already down approximately 15 per cent for 2026 before this announcement, making the 36 per cent single-day move a partial recovery, not a clean breakout above prior highs.

That context matters, because the approval does not resolve the harder question underneath it: what the European market will actually pay for Daybu, and when.

The regulatory barrier was the visible risk. The reimbursement structure is the one that remains open.

Chapter 2: Larger Market, Lower Prices

Europe holds more Rett syndrome patients than the United States — between 9,000 and 12,000 compared with 6,000 to 9,000 in the US — which is the number most investors cited in Monday's rally.

But the articles do not let that patient count translate cleanly into revenue.

In the US, Acadia Pharmaceuticals charges approximately US$375,000 per patient annually. European reimbursement systems do not work this way, and the articles are explicit: Acadia is unlikely to achieve anything close to that figure in Europe.

The divergence between what the two broker forecasts imply is the buried problem.

Bell Potter forecasts US$100 million in Daybu European sales in 2028. Canaccord projects peak non-US sales — mainly European — of US$250 million, a figure nearly two and a half times larger.

Both analysts are working from the same approval announcement. The gap between them is not a disagreement about whether the drug will sell; it is a disagreement about what European governments will agree to pay per patient.

Neither figure has been grounded by a disclosed pricing agreement, because Acadia has not yet entered reimbursement negotiations in Europe.

There is a second structural constraint the articles surface. The EU approval covers patients aged five and above, whereas the US label extends to patients two years and older. That age restriction directly limits the addressable patient count even within the approved population.

This is the paradox the 36 per cent move has not yet resolved. More patients, a wider geography across 27 member states plus Iceland and Norway — and yet the per-patient economics are entirely unestablished.

The US$35 million milestone Neuren receives on first EU commercial sale is fixed. The royalty stream that follows is not.

Chapter 3: What Actually Decides the Thesis

The European Commission's final decision is not the event that matters most for Neuren investors from here.

That decision is widely expected to confirm the CHMP recommendation — the articles treat it as close to a formality given the CHMP positive opinion.

The variable that decides the investment thesis is Acadia's reimbursement negotiation with European payers, which begins only after EC approval and moves country by country across 27 markets.

Canaccord does not expect Neuren to receive the US$35 million milestone payment until the December quarter of 2027. That timeline reflects how long it takes for one EU member state to list and reimburse a drug, even after federal approval.

The earliest leading indicator for the revenue path is what Acadia reports in its earnings calls through 2026 and 2027 about the pricing discussions it is holding in France, Germany, and the United Kingdom — the three markets with the largest patient populations and the most disclosure-intensive reimbursement processes.

A German pricing agreement, under AMNOG, would come with a published benefit assessment that sets a European reference point.

For investors already holding Neuren, the question is whether the move from approximately $12 to $16.60 has priced the full milestone or only the regulatory optionality. The stock's 15 per cent decline for 2026 before this announcement suggests that the market was discounting regulatory failure. The approval removes that discount. Whether the royalty trajectory beyond the milestone justifies prices above the current level depends entirely on what Acadia negotiates in the next 18 months.

For investors watching from the sidelines, the entry criterion is not the EC decision — that is already in the price. It is the first public signal of a European reimbursement rate, which surfaces Acadia's ability to convert the EU patient base into revenue at a price above the marginal cost of access programs.

If Acadia's early European disclosures suggest pricing at or above a level that supports Bell Potter's US$100 million 2028 forecast, the current share price is reasonable against the royalty stream. If the early pricing points run below that level, the 36 per cent move will prove to have over-discounted the upside, and the stock re-rates toward its prior range.

The trap version is a drug approved across 29 jurisdictions but reimbursed narrowly — the same outcome that has constrained several rare-disease launches in Europe over the last decade. The entry setup is a reimbursement framework in a major EU market that validates the Bell Potter base case before the December 2027 milestone date.